STUELPNAGEL JOHN R 4
4 · 10x Genomics, Inc. · Filed Dec 3, 2021
Insider Transaction Report
Form 4
STUELPNAGEL JOHN R
Director
Transactions
- Sale
Class A Common Stock
2021-12-01$154.02/sh−100$15,402→ 346,716 total - Sale
Class A Common Stock
2021-12-01$151.10/sh−1,700$256,869→ 347,916 total - Sale
Class A Common Stock
2021-12-01$155.55/sh−100$15,555→ 346,616 total - Sale
Class A Common Stock
2021-12-01$150.51/sh−2,000$301,022→ 349,616 total - Sale
Class A Common Stock
2021-12-01$151.79/sh−1,100$166,973→ 346,816 total
Footnotes (4)
- [F1]The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- [F2]This transaction was executed in multiple trades at prices ranging from $150.00 to $150.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]This transaction was executed in multiple trades at prices ranging from $151.00 to $151.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F4]This transaction was executed in multiple trades at prices ranging from $151.53 to $152.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.